#AbbVie — FinScans

Release 📈 Stocks

AbbVie Reports Positive Phase 1 Data for Metabolic Drug Candidate ABBV-295

September 30, 2026 (2 days ago)

AbbVie's ABBV-295 shows promising Phase 1 results with a long half-life, enabling potential bi-weekly dosing and strengthening the company's metabolic drug pipeline.

ABBV

🌍 AMERICAS Read More →

News 📈 Stocks

Biotech IPO Market Faces Scrutiny as 8 Firms Seek Capital for Clinical Trials

September 18, 2026 (13 days ago)

Investors are prioritizing clinical-stage biotechs with proven potential, as eight companies navigate the IPO process with varying degrees of market readiness and…

Grifols Electra Therapeutics Tarsier Therapeutics +6

🌍 GLOBAL Read More →

News 📋 Bonds

AbbVie Plans $10 Billion Bond Sale to Finance Apogee Therapeutics Acquisition

August 4, 2026 (58 days ago)

AbbVie launches a $10 billion bond offering to finance the Apogee Therapeutics deal, marking a major pharmaceutical M&A debt issuance in 2026.

APGE ABBV LQD

🌍 US Read More →

News 📈 Stocks

AbbVie Q2 Earnings Top Estimates; Botox Demand Revival Lifts Outlook

July 31, 2026 (62 days ago)

AbbVie beat Q2 earnings estimates fueled by Botox demand revival, sending shares higher.

ABBV

🌍 US Read More →

News 📈 Stocks

Galderma Shares Plunge After FDA Rejects Botox Rival Relfydess

July 1, 2026 (93 days ago)

Galderma shares sank after the FDA rejected its Botox rival Relfydess, delaying U.S. market entry and strengthening AbbVie's grip on the aesthetics…

GALD ABBV

🌍 CH Read More →